Abstract 648P
Background
CBP-1019 is a globally first-in-class bi-specific ligand drug conjugate (Bi-XDC) that targets both FRα and TRPV6 with the payload of exatecan (DX-8951), developed by Coherent Biopharma. Preclinical studies have shown that CBP-1019 with a MW of only 3 KD can deliver more payloads than TOPO-I ADCs with a favorable safety profile, demonstrating a therapeutic window of 15-30 folds greater. Up to 90%-100% TGI was observed in PDX models at the dose of 50-75 mg/kg (equivalent to 4 - 6 mg/kg in human). We designed a phase I/II study to evaluate the safety and efficacy of CBP-1019 in pts with advanced solid tumors (NCT05830097). Currently, we reported the results from the phase I study.
Methods
In phase I study, an accelerated titration design was employed for the first two dose levels (1.0, 2.0 mg/kg Q2W), followed by a standard "3+3” design for the subsequent dose levels (3.0 - 6.0 mg/kg Q2W). Dose expansion would be conducted in selected dose levels. The primary endpoints included safety, MTD, RP2D and ORR.
Results
By 31st Mar. 2024, 22 pts were enrolled (1.0 - 4.0 mg/kg), with median age of 59 years. All pts were heavily prior treated with median 4 lines of treatment. DLT was not observed and MTD not yet reached. Most TRAEs were grade 1 or 2. The most commonly ≥grade 3 TRAEs mainly in neutrophil count decreased (27.3%), platelet count decreased (18.2%), white blood cell count decreased (13.6%), anemia (9.1%) and lymphocyte count decreased (9.1%). 4 pts have been treated for over 4 months (the longest treatment duration is over 7 months) without AEs of interstitial pneumonia or ophthalmic toxicity occurred. Among 13 efficacy evaluable pts ≥ 2.0 mg/kg dose, 2 ovarian cancer pts with confirmed PR (maximum target lesion reduction was 66.0% and 34.0%, respectively) and 9 with SD were observed. The exposure of CBP-1019 and DX-8951 increased with dose escalation, without accumulation of either substance after multiple doses.
Conclusions
CBP-1019 as the first-in-class bi-XDC globally, was well-tolerated at 1.0 - 4.0 mg/kg Q2W without DLTs or other common severe toxicities observed in ADCs. Preliminary antitumor activity was seen at ≥2 mg/kg dose.
Clinical trial identification
NCT05830097.
Editorial acknowledgement
Legal entity responsible for the study
Coherent Biopharma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
744P - A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)
Presenter: Jung-Min Lee
Session: Poster session 01
745P - Biomarker-driven targeted therapy in platinum-resistant ovarian cancer (BRIGHT): An open-label, multicenter, umbrella trial
Presenter: Qinglei Gao
Session: Poster session 01
746P - Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression
Presenter: Lan Gardner Coffman
Session: Poster session 01
747P - SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)
Presenter: Clare Scott
Session: Poster session 01
748P - Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma
Presenter: Ana Oaknin
Session: Poster session 01
750P - Phase I safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)
Presenter: Claire Friedman
Session: Poster session 01